Related Experiment Videos
Immunoactive Properties of Cerebrolysin
Nataliya Yu. Sotnikova1, Olga A. Gromova, Elena A. Novikova
1Ivanovo State Medical Academy, Ivanovo, Russia.
Insights
Cerebrolysin treatment in children with minimal cerebral dysfunction improved immune status by increasing CD19(+) cells and normalizing immunoglobulin levels. T helper cell activation was also observed.
Area of Science:
- Immunology
- Pediatrics
- Neurology
Background:
- Minimal cerebral dysfunction (MCD) in children can be associated with immune system dysregulation.
- Understanding the impact of therapeutic interventions on immune markers in MCD is crucial.
Purpose of the Study:
- To investigate the effects of cerebrolysin on the immune status of children aged 3-8 years with MCD.
- To evaluate changes in lymphocyte subsets, immunoglobulin levels, and activation markers post-treatment.
Main Methods:
- Children with MCD received intramuscular cerebrolysin (1 ml/10 kg) for one month.
- Immune status was assessed before and after treatment, analyzing CD19(+), CD4(+), CD16(+) (NK) cells, serum IgG, IgA, and lymphocyte activation markers (CD25, HLA DR, CD95).
- In vitro studies examined T helper cell activation.
Main Results:
- Cerebrolysin administration led to an increase in CD19(+) cells and normalization of serum IgG and IgA levels.
- A rise in CD4(+) lymphocytes and normalization of CD16(+) (NK) cells were observed.
- Lymphocyte activation markers (CD25, HLA DR) normalized to control group levels, with no change in CD95 expression.
- In vitro analysis indicated cerebrolysin primarily activates T helper cells.
Conclusions:
- Cerebrolysin therapy positively modulates the immune status in children with minimal cerebral dysfunction.
- The treatment enhances B cell counts, normalizes immunoglobulin levels, and improves T cell subsets and NK cell counts.
- Cerebrolysin demonstrates immunomodulatory effects, particularly on T helper cells, suggesting a potential therapeutic benefit in MCD.
Abstract:
In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month. The cerebrolysin administration resulted in an increase in the level of CD19(+) cells with a simultaneous normalization of serum IgG and IgA levels. The count of CD4(+) lymphocytes has risen. Normalization of a relative count of CD16(+) cells (NK) was noted after cerebrolysin therapy. Expression of activation markers (CD25 and HLA DR) in total population of lymphocytes parallelly changed, achieving the parameters of the control group without any changes in expression of CD95 molecule. Under the cerebrolysin influence the activation mainly of T helpers could be observed in vitro.